Used in the treatment of estrogen receptor-positive (ER+) breast cancer, particularly in cases that are resistant to other hormonal therapies. It functions as a selective estrogen receptor degrader (SERD), effectively reducing the levels of estrogen receptors in cancer cells, thereby inhibiting tumor growth. Currently under investigation in clinical trials to evaluate its efficacy, safety, and optimal dosing, especially in combination with other targeted therapies. Its oral bioavailability makes it a promising candidate for long-term treatment regimens compared to injectable SERDs.